Frédéric PELONG, CFO of Valbiotis, will attend the CIC Market Solutions Forum, an opportunity for him to exchange with investors on the company’s new commercial strategy. This new strategy, announced October 7, 2022 aims to accelerate the growth of Valbiotis and to boost its capacity for innovation using two main levers: firstly, the signing of international partnerships (global or regional) with major players in the nutrition and healthcare sectors, supported by the specialist firm AEC Partners, and secondly, the company's own marketing of its products on the French market. This strategy applies to three active substances in development for the prevention of metabolic and cardiovascular diseases: TOTUM•070 against excess cholesterol, TOTUM•448 against metabolic liver disease and TOTUM•854 against high blood pressure. This dual strategy, creating value, will enable Valbiotis to rapidly target the global food supplement market, estimated at 250 billion euros in 2025, with annual growth of 9.6%.
Read the press release